Completed NA INTERVENTIONAL 1-arm NCT00613067

ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder (N1)

The Amplitude Change of the Auditory Evoked N1 Component as a Predictor of Response to Escitalopram Treatment in Patients With Generalized Anxiety Disorder

Sponsor: Inje University

Conditions Generalized Anxiety Disorder

Interventions escitalopram

Updated 6 times since 2017 Last updated: Jun 29, 2010 Started: Dec 31, 2007 Primary completion: Apr 30, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00613067, this NA trial focuses on Generalized Anxiety Disorder and remains completed. Sponsored by Inje University, it has been updated 6 times since 2007, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Inje University

Data source: Inje University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Goyang, South Korea